FDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks
Portfolio Pulse from Vandana Singh
The FDA has extended its review of Sarepta Therapeutics' SRP-9001 gene therapy for Duchenne muscular by a few weeks, with a new review date set for June 22. The agency is working towards potentially granting accelerated approval for SRP-9001, initially for use in Duchenne patients ages 4-5 years old. Sarepta's stock price has dropped 9.44% to $133.
May 24, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sarepta Therapeutics' stock price has dropped 9.44% to $133 after the FDA extended its review of the company's SRP-9001 gene therapy for Duchenne muscular.
The FDA's extension of the review for Sarepta's SRP-9001 gene therapy has caused uncertainty among investors, leading to a drop in the company's stock price. The potential for accelerated approval, however, could positively impact the stock in the future if the review is successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100